News Releases

Real-world evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer, according to research from the Abramson Cancer Center at the University of Pennsylvania.

A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania found significant disparities in the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs proven to treat type 2 diabetes, with usage remaining low with Black, Asian, and lower-income groups despite an increase in overall usage for patients with type 2 diabetes.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has selected Penn Medicine as one of five sites across the country to serve as a Center of Excellence for Influenza Research and Response (CEIRR), with the goal of better understanding influenza viruses around the world along with learning about the viral strains that have the potential to cause pandemics.

World renowned cancer cell therapy pioneer Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center, received the $1 million Sanford Lorraine Cross Award for his groundbreaking work in developing chimeric antigen receptor (CAR) T cell therapy.

Humans have a uniquely high density of sweat glands embedded in their skin—10 times the density of chimpanzees and macaques. Now, researchers at Penn Medicine have discovered how this distinctive, hyper-cooling trait evolved in the human genome.

Residents in majority-Black neighborhoods experience higher rates of severe pregnancy-related health problems than those living in predominantly-white areas, according to a new study of pregnancies at a Philadelphia-based health system, which was led by researchers in the Perelman School of Medicine at the University of Pennsylvania.

A new biosealant therapy may help to stabilize injuries that cause cartilage to break down, paving the way for a future fix or – even better – begin working right away with new cells to enhance healing, according to a new animal-based study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.